Skip to main content
ConductScienceScienceDex
NIH funding notice PAR-19-214

Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)

Closed on February 21, 2022.

Posted
March 8, 2019
Close date
February 21, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $734,247 in first-year total cost, median $734,247.

Most frequent study sections

  1. Special Emphasis Panel[ZMH1 ERB-N (02)]1

Most frequent institutions

  1. MASSACHUSETTS GENERAL HOSPITAL1
Competing awards under PAR-19-214 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021Optimizing sleep spindle measurements as translational assays of memory consolidation1UG3MH125273-01MANOACH, DARA SVARELA, CARMENMASSACHUSETTS GENERAL HOSPITAL, MA$734,247ZMH1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
PAR-19-214: Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) | ScienceDex | ConductScience